www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Home / Understanding big issues

National blueprint prescribes shot in the arm for drugs companies

By Wang Wen (China Daily)

Updated: 2016-03-08 08:16:21

8.03K

The constant use of phrases such as "biological medicine", "healthcare reform" and "a healthy China" in the country's 13th Five-Year Plan (2016-20) has encouraged pharmaceutical companies, both Chinese and foreign, to expand their development programs.

According to the plan, the move is intended "to strengthen the prevention and cure of infectious, chronic and endemic diseases", and a number of pharmaceutical manufacturers and medical supplies companies will adapt their research and development programs to fit the requirements.

"We have already adjusted the direction of our research to focus on market demand, in accordance with the plan," said Hu Jiqiang, chairman of Conba Group, in Hangzhou, Zhejiang province, who is a deputy to the National People's Congress.

Chronic illnesses, such as cardiovascular and respiratory obstructions, will remain the company's core field over the next five years, Hu said.

He added that Conba - which focuses on respiratory and cardiovascular diseases - is also working on eight new treatments for respiratory illness. "We expect to gain advantages in this field in the coming years," he said.

Feng Danlong, director of corporate affairs for China at Pfizer and a member of the 12th National Committee of the Chinese People's Political Consultative Conference, proposed a stronger focus on the management of dyslipidemia - excessive levels of fat in the blood - to reduce the incidence of cardiovascular disease.

Biological medicine is also referred to several times in the plan, and the government has already taken a number of steps to support the sector, according to An Kang, chairman of Hualan Biological Engineering, China's largest manufacturer of human blood products, which is based in Henan province.

"The government has given us great support with the policies related to technological research," he said.

The wording of the plan has encouraged the company to establish a research and development center that will also include an "academic workstation" that will offer opportunities for academic research, he said.

In the next five years, Hualan Bio will continue to add to its product range and narrow the gap with foreign competitors, he added.

Foreign companies also have great expectations for China's healthcare reform, which will be deepened during the period of the plan.

"We expect substantial progress in the implementation of healthcare-reform policies in the coming five years," said Yin Xudong, chairman of Novartis Greater China.

The approval process for new drugs could also be accelerated to reduce the current five-year waiting period in the introduction of innovative new drugs in China, Yin said.

The quality standards, which ensure that patients have access to safe, high-quality generic drugs, could also be raised, he said.

主站蜘蛛池模板: 一本色道久久88亚洲精品综合 | 欧美顶级毛片在线播放 | 欧洲美女与男人做爰 | 久久亚洲综合 | 亚洲人成网址在线播放a | 亚洲欧美日韩色 | 美女张开腿让男人 | 最新主播福利视频在线观看 | 久久综合综合久久 | 精品欧美成人高清视频在线观看 | 国产日产亚洲系列首页 | 欧美亚洲国产精品久久久 | 国产激爽大片在线播放 | 男女牲高爱潮免费视频男女 | 一本高清 | 日韩特级毛片免费观看视频 | 国产精品成人观看视频免费 | 国产亚洲人成网站在线观看不卡 | 欧美孕交视频 | 国产乱肥老妇精品视频 | www.亚洲天堂网 | 久久不见久久见免费影院www日本 | 怡红院在线观看在线视频 | 久久欧美久久欧美精品 | 99精品视频在线免费观看 | 九九精品免视频国产成人 | 国产在线日韩在线 | 在线视频 国产交换 | 成人午夜毛片 | 久久一区二区精品综合 | 国产精品不卡 | 国产欧美一区二区精品久久久 | 亚洲午夜影视 | 国产精品亚洲一区二区三区 | 韩国啪啪网站 | 日本视频在线免费播放 | 成年女人毛片免费观看97 | 高清免费国产在线观看 | 国产精品一级香蕉一区 | 爽爽日本在线视频免费 | v欧美精品v日本精品 |